TUDCA (Tauroursodeoxycholic Acid)
A taurine-conjugated bile acid that acts as a chemical chaperone, easing endoplasmic reticulum stress. The mechanism is genuinely interesting and the liver rationale is sound — but the human outcome data are smaller than the supplement marketing implies, and the highest-profile clinical programme built on it failed in phase 3.
Reviewed & fact-checked by
BiohackingHub Research TeamEditorial Research Team · Last updated: July 31, 2026
Medical Disclaimer: The information on this page is for educational and research purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
What Is TUDCA?
TUDCA is the taurine conjugate of ursodeoxycholic acid — a bile acid that occurs naturally in humans in small amounts and, famously, in far larger amounts in bear bile, which is where traditional use originated. Modern supply is synthetic.
Its interest to biohackers comes from a mechanism that has nothing to do with digestion: TUDCA behaves as a chemical chaperone. When the endoplasmic reticulum accumulates misfolded proteins, the cell mounts an "unfolded protein response" that, sustained, drives inflammation and apoptosis. TUDCA dampens that response. Because ER stress shows up in liver disease, insulin resistance, and neurodegeneration alike, one compound ends up touching several stories.
What the Human Data Actually Show
Insulin sensitivity. A small mechanistic trial in obese adults found that four weeks of TUDCA improved hepatic and muscle insulin sensitivity — but not adipose tissue. This is a real human result and the most-cited metabolic finding. It is also a small, short study of a surrogate outcome.
Bile acid handling. Work in primary biliary cholangitis established that TUDCA and plain UDCA are metabolised and distributed differently, with the taurine-conjugated form enriching the bile pool distinctly. This is the strongest ground: TUDCA is a legitimate bile acid therapy, and the liver use case follows from it.
Neurodegeneration — the cautionary tale. An early phase 2 trial in ALS was encouraging, and the phenylbutyrate–taurursodiol combination showed promise in the CENTAUR trial and received approval. Then the phase 3 confirmatory trial failed and the product was withdrawn. A European phase 3 of TUDCA on its own is the outstanding test. The lesson is not that the mechanism is wrong; it is that chaperone activity in a dish does not reliably become benefit in a patient.
Dosage
| Parameter | Recommendation |
|---|---|
| Low | 250 mg/day |
| Typical | 500 mg/day |
| High | 1000 mg/day (split) |
| Timing | With meals; split doses above 500 mg |
| Practical ceiling | Loose stools, not toxicity, is what stops most people |
Safety
TUDCA is generally well tolerated, and diarrhoea is the dose-limiting effect. The genuine contraindications are structural: complete biliary obstruction, acute cholecystitis, or cholangitis — situations where increasing bile flow is exactly wrong. Skip it in pregnancy on insufficient-data grounds. Bile acid sequestrants and aluminium antacids bind it, so separate doses by several hours. Anyone with diagnosed liver or gallbladder disease should be taking this under a clinician, not off a forum recommendation.
Related Research
Stacking Interactions
How TUDCA (Tauroursodeoxycholic Acid) interacts with other compounds
Same bile acid family — combining them stacks the same mechanism and the same diarrhoea risk without added benefit
Protocols using TUDCA (Tauroursodeoxycholic Acid)
Evidence-graded stacks that include this compound
Safety Profile — Tier B
Generally safe — moderate evidence
Contraindications
- ●Complete biliary obstruction
- ●Acute cholecystitis or cholangitis
- ●Pregnancy and breastfeeding — insufficient data
Side Effects
- ●Loose stools and diarrhoea — the dose-limiting effect for most people
- ●Mild nausea or abdominal discomfort
- ●Rare: transient rise in liver enzymes